The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Open accessAbstract
The study of T regulatory cells (T reg cells) has been limited by the lack of specific surface markers and an inability to define mechanisms of suppression. We show that the expression of CD39/ENTPD1 in concert with CD73/ecto-5′-nucleotidase distinguishes CD4+/CD25+/Foxp3+ T reg cells from other T cells. These ectoenzymes generate pericellular adenosine from extracellular nucleotides. The coordinated expression of CD39/CD73 on T reg cells and the adenosine A2A receptor on activated T effector cells generates immunosuppressive loops, indicating roles in the inhibitory function of T reg cells. Consequently, T reg cells from Cd39-null mice show impaired suppressive properties in vitro and fail to block allograft rejection in vivo. We conclude that CD39 and CD73 are surface markers of T reg cells that impart a specific biochemical signature characterized by adenosine generation that has functional relevance for cellular immunoregulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Self-citationPark, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Sakaguchi, S. (2000) · Cell · doi:10.1016/s0092-8674(00)80856-9 · Cited by 1,815
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Eltzschig, H. K., & Carmeliet, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910283 · Cited by 2,061
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1609337 · Cited by 1,296
Pandiyan, P., Zheng, L., Ishihara, S., Reed, J., & Lenardo, M. J. (2007) · Nature Immunology · doi:10.1038/ni1536 · Cited by 1,286
CD39 and CD73 in immunity and inflammation
Antonioli, L., Pacher, P., Vizi, E. S., & Haskó, G. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.03.005 · Cited by 1,263
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
Self-citationYegutkin, G. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.024 · Cited by 1,154
Th17 and regulatory T cells in mediating and restraining inflammation
Littman, D. R., & Rudensky, A. Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.021 · Cited by 1,039
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation
Tang, Q., & Bluestone, J. A. (2008) · Nature Immunology · doi:10.1038/ni1572 · Cited by 1,031
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Cellular function and molecular structure of ecto-nucleotidases
Zimmermann, H., Zebisch, M., & Sträter, N. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9309-4 · Cited by 977
Regulation of the immune response by the aryl hydrocarbon receptor
Gutiérrez-Vázquez, C., & Quintana, F. J. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.012 · Cited by 985
Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses
Zheng, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J. M., Chu, T.-T., Corcoran, L., Treuting, P., Klein, U., & Rudensky, A. Y. (2009) · Nature · doi:10.1038/nature07674 · Cited by 958
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Self-citationMetabolic Interactions in the Tumor Microenvironment
Lyssiotis, C. A., & Kimmelman, A. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.003 · Cited by 853
Nucleotide signalling during inflammation
Idzko, M., Ferrari, D., & Eltzschig, H. K. (2014) · Nature · doi:10.1038/nature13085 · Cited by 902
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Self-citationEvolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008) · Physiological Reviews · doi:10.1152/physrev.00035.2007 · Cited by 862
Self-citationRegulatory T cells: how do they suppress immune responses?
Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P., & Yamaguchi, T. (2009) · International Immunology · doi:10.1093/intimm/dxp095 · Cited by 854
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
Immune cell regulation by autocrine purinergic signalling
Junger, W. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri2938 · Cited by 810
Purinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
Self-citationPharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Molecular Mechanisms of Treg-Mediated T Cell Suppression
Schmidt, A., Oberle, N., & Krammer, P. H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00051 · Cited by 761
Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine
Kayama, H., Okumura, R., & Takeda, K. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070119-115104 · Cited by 747
Regulatory T cells and infection: a dangerous necessity
Belkaid, Y. (2007) · Nature Reviews Immunology · doi:10.1038/nri2189 · Cited by 745
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Purinergic Signaling during Inflammation
Eltzschig, H. K., Sitkovsky, M. V., & Robson, S. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1205750 · Cited by 706
Self-citationIncreased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Cillo, A. R., Kürten, C. H. L., Tabib, T., Qi, Z., Onkar, S., Wang, T., Liu, A., Duvvuri, U., Kim, S., Soose, R. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.11.014 · Cited by 668
van de Veen, W., Stanic, B., Yaman, G., Wawrzyniak, M., Söllner, S., Akdis, D. G., Rückert, B., Akdis, C. A., & Akdis, M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.014 · Cited by 652
Calcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., Cova, A., Canese, R., Jachetti, E., Rossetti, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1272 · Cited by 640
B cell regulation in cancer and anti-tumor immunity
Sarvaria, A., Madrigal, J. A., & Saudemont, A. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.35 · Cited by 630
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Purinergic Signaling during Inflammation
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1300259 · Cited by 608
The regulation of immune tolerance by FOXP3
Lu, L., Barbi, J., & Pan, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.75 · Cited by 580
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 572
Self-citationExtracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202366109 · Cited by 560
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 543
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis
Carvelli, J., Demaria, O., Vély, F., Batista, L., Chouaki Benmansour, N., Fares, J., Carpentier, S., Thibult, M.-L., Morel, A., Remark, R., et al. (2020) · Nature · doi:10.1038/s41586-020-2600-6 · Cited by 526
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Takenaka, M. C., Gabriely, G., Rothhammer, V., Mascanfroni, I. D., Wheeler, M. A., Chao, C.-C., Gutiérrez-Vázquez, C., Kenison, J., Tjon, E. C., Barroso, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0370-y · Cited by 517
Self-citationZarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., & Powell, J. D. (2008) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 515
Self-citationChaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Regulatory Lymphocytes and Intestinal Inflammation
Izcue, A., Coombes, J. L., & Powrie, F. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132657 · Cited by 507
From purines to purinergic signalling: molecular functions and human diseases
Huang, Z., Xie, N., Illes, P., Di Virgilio, F., Ulrich, H., Semyanov, A., Verkhratsky, A., Sperlagh, B., Yu, S.-G., Huang, C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00553-z · Cited by 489
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481
Damage-associated molecular patterns in cancer: a double-edged sword
Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 480
CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis
Fletcher, J. M., Lonergan, R., Costelloe, L., Kinsella, K., Moran, B., O'Farrelly, C., Tubridy, N., & Mills, K. H. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901881 · Cited by 476
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Regulatory T Cells in the Control of Host-Microorganism Interactions
Belkaid, Y., & Tarbell, K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132723 · Cited by 468
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Nakao, Y., Fukuda, T., Zhang, Q., Sanui, T., Shinjo, T., Kou, X., Chen, C., Liu, D., Watanabe, Y., Hayashi, C., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.046 · Cited by 466
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Methotrexate—how does it really work?
Chan, E. S. L., & Cronstein, B. N. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.5 · Cited by 459
NT5E Mutations and Arterial Calcifications
St. Hilaire, C., Ziegler, S. G., Markello, T. C., Brusco, A., Groden, C., Gill, F., Carlson-Donohoe, H., Lederman, R. J., Chen, M. Y., Yang, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0912923 · Cited by 455
Principles of regulatory T cell function
Dikiy, S., & Rudensky, A. Y. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.004 · Cited by 445
Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α
Mascanfroni, I. D., Takenaka, M. C., Yeste, A., Patel, B., Wu, Y., Kenison, J. E., Siddiqui, S., Basso, A. S., Otterbein, L. E., Pardoll, D. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3868 · Cited by 439
Self-citationThe P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
Savio, L. E. B., de Andrade Mello, P., da Silva, C. G., & Coutinho-Silva, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00052 · Cited by 437
Jin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., Shin, T., Curiel, T. J., & Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3109 · Cited by 432
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Sionov, R. V., Fridlender, Z. G., & Granot, Z. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0147-5 · Cited by 416
Purinergic Control of T Cell Activation by ATP Released Through Pannexin-1 Hemichannels
Schenk, U., Westendorf, A. M., Radaelli, E., Casati, A., Ferro, M., Fumagalli, M., Verderio, C., Buer, J., Scanziani, E., & Grassi, F. (2008) · Science Signaling · doi:10.1126/scisignal.1160583 · Cited by 411
NF‐κB: roles and regulation in different CD 4+ T‐cell subsets
Oh, H., & Ghosh, S. (2013) · Immunological Reviews · doi:10.1111/imr.12033 · Cited by 408
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells
Canale, F. P., Ramello, M. C., Núñez, N., Furlan, C. L. A., Bossio, S. N., Serrán, M. G., Boari, J. T., del Castillo, A., Ledesma, M., Sedlik, C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-16-2684 · Cited by 408
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target
Sojka, D. K., Huang, Y., & Fowell, D. J. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02813.x · Cited by 393
Yang, D., Han, Z., & Oppenheim, J. J. (2017) · Immunological Reviews · doi:10.1111/imr.12577 · Cited by 405
Shechter, R., London, A., & Schwartz, M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3391 · Cited by 403
Regulatory T cells in cardiovascular diseases
Meng, X., Yang, J., Dong, M., Zhang, K., Tu, E., Gao, Q., Chen, W., Zhang, C., & Zhang, Y. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.169 · Cited by 402
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401
CD39/CD73/A2AR pathway and cancer immunotherapy
Xia, C., Yin, S., To, K. K. W., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01733-x · Cited by 399
Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
Helios Expression Is a Marker of T Cell Activation and Proliferation
Akimova, T., Beier, U. H., Wang, L., Levine, M. H., & Hancock, W. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024226 · Cited by 389
CD39 Expression Identifies Terminally Exhausted CD8+ T Cells
Gupta, P. K., Godec, J., Wolski, D., Adland, E., Yates, K., Pauken, K. E., Cosgrove, C., Ledderose, C., Junger, W. G., Robson, S. C., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005177 · Cited by 396
Self-citationImmune crosstalk in cancer progression and metastatic spread: a complex conversation
Garner, H., & de Visser, K. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0271-z · Cited by 395
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Young, A., Ngiow, S. F., Gao, Y., Patch, A.-M., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 391
Self-citation
Metadata
- Authors
- Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., Kuchroo, V. K., Strom, T. B., & Robson, S. C.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2007-05-14
- Volume
- 204
- Issue
- 6
- Pages
- 1257-1265
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2106190040
- Cited by
- 2,470
- References
- 38
- FWCI
- 56.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.